| human | Q5 |
| P9795 | ARPI author ID | 02211 |
| P1960 | Google Scholar author ID | XIyHXBkAAAAJ |
| P6634 | LinkedIn personal profile ID | elisa-paolicchi-ba87a230 |
| P496 | ORCID iD | 0000-0001-6101-7576 |
| P2038 | ResearchGate profile ID | Elisa_Paolicchi |
| P396 | SBN author ID | CFIV319707 |
| P1153 | Scopus author ID | 51864396500 |
| P214 | VIAF ID | 61144928030654341490 |
| P69 | educated at | University of Pisa | Q645663 |
| P108 | employer | University of Pisa | Q645663 |
| National Cancer Institute | Q664846 | ||
| VU University Medical Center | Q1888218 | ||
| University of Salford | Q2738622 | ||
| P734 | family name | Paolicchi | Q101041546 |
| Paolicchi | Q101041546 | ||
| Paolicchi | Q101041546 | ||
| P735 | given name | Elisa | Q1168432 |
| Elisa | Q1168432 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q35163440 | A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients |
| Q39322941 | A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma |
| Q27851670 | An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients |
| Q47981988 | An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw. |
| Q62976255 | EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle |
| Q37940106 | Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies |
| Q30413307 | Histone lysine demethylases in breast cancer |
| Q35836756 | Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer |
| Q35160562 | Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk |
| Q48657228 | Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk |
| Q37960266 | Polycomb genes and cancer: time for clinical application? |
| Q26767351 | Targeting hypoxic response for cancer therapy |
| Q51541898 | Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients. |
Search more.